Neuroprotective effect of selective kappa opioid receptor agonist is gender specific and linked to reduced neuronal nitric oxide

Emil Zeynalov, Masaaki Nemoto, Patricia D. Hurn, Raymond C. Koehler, Anish Bhardwaj

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

We have previously shown that treatment with selective kappa-opioid receptor agonist BRL 52537 hydrochloride [(±)-1-(3,4-dichlorophenyl) acetyl-2-(1-pyrrolidinyl) methylpiperidine] (1) has a long therapeutic window for providing ischemic neuroprotection and (2) attenuates ischemia-evoked nitric oxide (NO) production in vivo in rats. Neuronally derived NO has been shown to be deleterious in the male, but not in the female, rodent model of focal ischemic stroke. We sought to determine if the agent fails to protect ischemic brain when neuronal NO synthase (nNOS) is genetically deleted in male, but not female, mice. Halothane-anesthetized adult male and female nNOS null mutants (nNOS-/-) and the genetically matched wildtype (WT) strain were subjected to transient (2 h) middle cerebral artery occlusion by the intraluminal filament technique. Vehicle or BRL 52537 treatment with continuous intravenous infusion was instituted at the onset of reperfusion and continued for 22 h. In WT male mice, infarct volumes measured at 72 h of reperfusion were robustly decreased with BRL 52537 treatment. In contrast, BRL 52537 did not decrease infarct volume in male nNOS-/- mice. BRL 52537 had no effect in the WT or nNOS-/- female mice. These data support that BRL 5253's mechanism of neuroprotection in vivo is through attenuation of nNOS activity and ischemia-evoked NO production. Neuroprotective effects of BRL 52537 are lost in the male when nNOS is not present; therefore, BRL 52537 likely acts upstream from NO generation and its subsequent neurotoxicity.

Original languageEnglish (US)
Pages (from-to)414-420
Number of pages7
JournalJournal of Cerebral Blood Flow and Metabolism
Volume26
Issue number3
DOIs
StatePublished - Mar 2006
Externally publishedYes

Fingerprint

kappa Opioid Receptor
Neuroprotective Agents
Nitric Oxide
Nitric Oxide Synthase
Reperfusion
Ischemia
Nitric Oxide Synthase Type I
1-(3,4-dichlorophenyl)acetyl-2-(1-pyrrolidinyl)methylpiperidine
Middle Cerebral Artery Infarction
Halothane
Therapeutics
Intravenous Infusions
Rodentia
Stroke
Brain

Keywords

  • Excitotoxic
  • Focal cerebral ischemia
  • Gender
  • Infarct
  • Kappa opioid receptor
  • Nitric oxide
  • Reperfusion

ASJC Scopus subject areas

  • Endocrinology
  • Neuroscience(all)
  • Endocrinology, Diabetes and Metabolism

Cite this

Neuroprotective effect of selective kappa opioid receptor agonist is gender specific and linked to reduced neuronal nitric oxide. / Zeynalov, Emil; Nemoto, Masaaki; Hurn, Patricia D.; Koehler, Raymond C.; Bhardwaj, Anish.

In: Journal of Cerebral Blood Flow and Metabolism, Vol. 26, No. 3, 03.2006, p. 414-420.

Research output: Contribution to journalArticle

@article{d54628ad884c4a14b4f20f2852fd5fd6,
title = "Neuroprotective effect of selective kappa opioid receptor agonist is gender specific and linked to reduced neuronal nitric oxide",
abstract = "We have previously shown that treatment with selective kappa-opioid receptor agonist BRL 52537 hydrochloride [(±)-1-(3,4-dichlorophenyl) acetyl-2-(1-pyrrolidinyl) methylpiperidine] (1) has a long therapeutic window for providing ischemic neuroprotection and (2) attenuates ischemia-evoked nitric oxide (NO) production in vivo in rats. Neuronally derived NO has been shown to be deleterious in the male, but not in the female, rodent model of focal ischemic stroke. We sought to determine if the agent fails to protect ischemic brain when neuronal NO synthase (nNOS) is genetically deleted in male, but not female, mice. Halothane-anesthetized adult male and female nNOS null mutants (nNOS-/-) and the genetically matched wildtype (WT) strain were subjected to transient (2 h) middle cerebral artery occlusion by the intraluminal filament technique. Vehicle or BRL 52537 treatment with continuous intravenous infusion was instituted at the onset of reperfusion and continued for 22 h. In WT male mice, infarct volumes measured at 72 h of reperfusion were robustly decreased with BRL 52537 treatment. In contrast, BRL 52537 did not decrease infarct volume in male nNOS-/- mice. BRL 52537 had no effect in the WT or nNOS-/- female mice. These data support that BRL 5253's mechanism of neuroprotection in vivo is through attenuation of nNOS activity and ischemia-evoked NO production. Neuroprotective effects of BRL 52537 are lost in the male when nNOS is not present; therefore, BRL 52537 likely acts upstream from NO generation and its subsequent neurotoxicity.",
keywords = "Excitotoxic, Focal cerebral ischemia, Gender, Infarct, Kappa opioid receptor, Nitric oxide, Reperfusion",
author = "Emil Zeynalov and Masaaki Nemoto and Hurn, {Patricia D.} and Koehler, {Raymond C.} and Anish Bhardwaj",
year = "2006",
month = "3",
doi = "10.1038/sj.jcbfm.9600196",
language = "English (US)",
volume = "26",
pages = "414--420",
journal = "Journal of Cerebral Blood Flow and Metabolism",
issn = "0271-678X",
publisher = "Nature Publishing Group",
number = "3",

}

TY - JOUR

T1 - Neuroprotective effect of selective kappa opioid receptor agonist is gender specific and linked to reduced neuronal nitric oxide

AU - Zeynalov, Emil

AU - Nemoto, Masaaki

AU - Hurn, Patricia D.

AU - Koehler, Raymond C.

AU - Bhardwaj, Anish

PY - 2006/3

Y1 - 2006/3

N2 - We have previously shown that treatment with selective kappa-opioid receptor agonist BRL 52537 hydrochloride [(±)-1-(3,4-dichlorophenyl) acetyl-2-(1-pyrrolidinyl) methylpiperidine] (1) has a long therapeutic window for providing ischemic neuroprotection and (2) attenuates ischemia-evoked nitric oxide (NO) production in vivo in rats. Neuronally derived NO has been shown to be deleterious in the male, but not in the female, rodent model of focal ischemic stroke. We sought to determine if the agent fails to protect ischemic brain when neuronal NO synthase (nNOS) is genetically deleted in male, but not female, mice. Halothane-anesthetized adult male and female nNOS null mutants (nNOS-/-) and the genetically matched wildtype (WT) strain were subjected to transient (2 h) middle cerebral artery occlusion by the intraluminal filament technique. Vehicle or BRL 52537 treatment with continuous intravenous infusion was instituted at the onset of reperfusion and continued for 22 h. In WT male mice, infarct volumes measured at 72 h of reperfusion were robustly decreased with BRL 52537 treatment. In contrast, BRL 52537 did not decrease infarct volume in male nNOS-/- mice. BRL 52537 had no effect in the WT or nNOS-/- female mice. These data support that BRL 5253's mechanism of neuroprotection in vivo is through attenuation of nNOS activity and ischemia-evoked NO production. Neuroprotective effects of BRL 52537 are lost in the male when nNOS is not present; therefore, BRL 52537 likely acts upstream from NO generation and its subsequent neurotoxicity.

AB - We have previously shown that treatment with selective kappa-opioid receptor agonist BRL 52537 hydrochloride [(±)-1-(3,4-dichlorophenyl) acetyl-2-(1-pyrrolidinyl) methylpiperidine] (1) has a long therapeutic window for providing ischemic neuroprotection and (2) attenuates ischemia-evoked nitric oxide (NO) production in vivo in rats. Neuronally derived NO has been shown to be deleterious in the male, but not in the female, rodent model of focal ischemic stroke. We sought to determine if the agent fails to protect ischemic brain when neuronal NO synthase (nNOS) is genetically deleted in male, but not female, mice. Halothane-anesthetized adult male and female nNOS null mutants (nNOS-/-) and the genetically matched wildtype (WT) strain were subjected to transient (2 h) middle cerebral artery occlusion by the intraluminal filament technique. Vehicle or BRL 52537 treatment with continuous intravenous infusion was instituted at the onset of reperfusion and continued for 22 h. In WT male mice, infarct volumes measured at 72 h of reperfusion were robustly decreased with BRL 52537 treatment. In contrast, BRL 52537 did not decrease infarct volume in male nNOS-/- mice. BRL 52537 had no effect in the WT or nNOS-/- female mice. These data support that BRL 5253's mechanism of neuroprotection in vivo is through attenuation of nNOS activity and ischemia-evoked NO production. Neuroprotective effects of BRL 52537 are lost in the male when nNOS is not present; therefore, BRL 52537 likely acts upstream from NO generation and its subsequent neurotoxicity.

KW - Excitotoxic

KW - Focal cerebral ischemia

KW - Gender

KW - Infarct

KW - Kappa opioid receptor

KW - Nitric oxide

KW - Reperfusion

UR - http://www.scopus.com/inward/record.url?scp=33644528136&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33644528136&partnerID=8YFLogxK

U2 - 10.1038/sj.jcbfm.9600196

DO - 10.1038/sj.jcbfm.9600196

M3 - Article

C2 - 16049424

AN - SCOPUS:33644528136

VL - 26

SP - 414

EP - 420

JO - Journal of Cerebral Blood Flow and Metabolism

JF - Journal of Cerebral Blood Flow and Metabolism

SN - 0271-678X

IS - 3

ER -